These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17362461)

  • 1. Surgical treatment of age-related macular degeneration: will there be a role in the future?
    Wong D; Durnian JM
    Clin Exp Ophthalmol; 2007 Mar; 35(2):167-73. PubMed ID: 17362461
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M; Sharma S
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
    Fong DS; Custis P; Howes J; Hsu JW
    Ophthalmology; 2010 Feb; 117(2):298-302. PubMed ID: 19969368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR; Del Priore LV
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
    Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
    Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.
    Garg S; Brod R; Kim D; Lane RG; Maguire J; Fischer D
    Clin Exp Ophthalmol; 2008 Apr; 36(3):252-6. PubMed ID: 18412594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab in ophthalmology: the controversy moves forward.
    Gillies MC
    Clin Exp Ophthalmol; 2010 May; 38(4):333-4. PubMed ID: 20642588
    [No Abstract]   [Full Text] [Related]  

  • 8. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
    Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
    Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
    Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
    Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-VEGF therapy: riding the wave of change.
    Hunyor AP
    Clin Exp Ophthalmol; 2008 Jul; 36(5):401-2. PubMed ID: 18925912
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab for the treatment of neovascular age-related macular degeneration.
    Pitlick JM; Vecera KF; Barnes KN; Reski JW; Forinash AB
    Ann Pharmacother; 2012 Feb; 46(2):290-6. PubMed ID: 22274144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of intravitreal bevacizumab followed by ranibizumab for the treatment of neovascular age-related macular degeneration.
    Stepien KE; Rosenfeld PJ; Puliafito CA; Feuer W; Shi W; Al-Attar L; Dubovy SR; Murray TG; Davis JL; Lee WH; Schwartz SG; Smiddy WE; Berrocal AM; Flynn HW
    Retina; 2009 Sep; 29(8):1067-73. PubMed ID: 19696701
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab: not as good with more adverse reactions?
    Beaumont P
    Clin Exp Ophthalmol; 2011 Aug; 39(6):588-90. PubMed ID: 21631687
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doctors warn against using Avastin for macular degeneration.
    Kmietowicz Z
    BMJ; 2010 May; 340():c2483. PubMed ID: 20453011
    [No Abstract]   [Full Text] [Related]  

  • 16. Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    Aujla JS
    Clin Exp Optom; 2012 Sep; 95(5):538-40. PubMed ID: 22621684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
    Chen G; Li W; Tzekov R; Jiang F; Mao S; Tong Y
    Retina; 2015 Feb; 35(2):187-93. PubMed ID: 25105318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
    El-Mollayess GM; Noureddine BN; Bashshur ZF
    Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab (AVASTIN) and age-related macular degeneration. Lower cost does not justify taking risks.
    Prescrire Int; 2015 Sep; 24(163):201-4. PubMed ID: 26417625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Age-related macular degeneration. Part 2: Therapeutic procedures].
    Wachtlin J; Gamulescu MA
    Klin Monbl Augenheilkd; 2012 Oct; 229(10):1049-59; quiz 1060-1. PubMed ID: 23225325
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.